Reckitt Benckiser

To see an up-to date selection of historical analyses and insights on Reckitt Benckiser, visit our new, dynamically updated Company Summary report pages for Reckitt Benckiser.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Reckitt Benckiser are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Reckitt Benckiser, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers
  Annual Sales WW - Sales Growth per Year (%)
  Rank Product Generic Name Pharmacological Class 2006 2007 2007
Reckitt Benckiser 1 Nurofen ibuprofen NSAID 308 410   33%  
  2 Suboxone buprenorphine & naloxone Opioid agonist & opioid antagonist 194 320   65%  
  3 Strepsils dichlorobenzyl alcohol & amylmetacresol Anti-bacterial 180 235   31%  
 
  Note: Shaded Cells  

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Reckitt Benckiser - Emezine Gastro-Intestinal Anti-emetics Dopamine D2 antagonist Phase III
  - V1004 Central Nervous System Narcotic analgesics Opioid agonist Pre-clinical
  - V1005 Central Nervous System Other CNS drugs Opioid agonist Pre-clinical

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
Reckitt Benckiser
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
       Market Capitalisation 29,493 29,493
       PE Ratio (diluted) - Normalised (x) 25.4 21.0
 
     Valuing the Enterprise
       Enterprise Value 30,363 30,363
       Free Cash Flow (Pre-Dividends) 1,404 1,816
       FCF Yield (%) 4.6% 6.0%
 
 Forecast Financials
  Income Statement
     Total Revenues 7,602 9,073
     Cost of Goods Sold (3,431) (3,932)
     S,G & A (2,578) (3,113)
     R&D (115) (151)
     Other Income/ Expense - Net 49 76
     EBIT - Normalised 1,528 1,952
     Net Interest & Financial Items 65 (66)
     Pre-tax Profits - Normalised 1,594 1,886
     Exceptionals - (275)
     Income Before Taxes 1,594 1,611
     Tax (377) (369)
     Tax Rate (%) 23.6% 22.9%
     Net Income - Reported 1,217 1,242
     Net Income - Normalised 1,217 1,454
 
  Per Share Data
     EPS - Diluted 1.64 1.69
     EPS - Basic 1.67 1.72
     EPS - Normalised (diluted) 1.64 1.98
     EPS - Normalised (basic) 1.67 2.02
     Avg. Shares Outstanding - Diluted 743.3 734.2
     Avg. Shares Outstanding - Basic 727.1 720.7
     DPS 0.63 0.89

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Reckitt Benckiser Acriflex chlorhexidine
  Anethaine tetracaine
  Asilone aluminium hydroxide & dimethicone
  Balneum urea & lauromacrogols
  Bonjela cetalkonium chloride & choline salicylate
  Cardiprin aspirin
  Clearasil triclosan
  Codis aspirin & codeine
  Curatoderm tacalcitol
  Delsym dextromethorphan
  Dequa range dequalinium chloride
  Disprin aspirin
  Disprol acetaminophen
  E45 edetate calcium disodium, paraffin liquid & tocopherol
  Emezine prochlorperazine
  Erdosteine erdosteine
  Fybogel psyllium
  Gaviscon sodium alginate, sodium bicarbonate & calcium carbonate
  Guaifenesin ER Rx guaifenesin & codeine
  Karvol menthol
  Lemsip acetaminophen
  Lipocine Collaboration -
  Lutsine dimethicone, paraffin liquid & tocopherol
  Mucinex D guaifenesin & pseudoephedrine
  Mucinex DM dextromethorphan & guaifenesin
  Mucinex Nasal Spray guaifenesin & oxymetazoilne
  Mucinex SE/Humibid guaifenesin
  Mycil tolnaftate
  Nurofen ibuprofen
  Nylax senna
  Optrex hamamelis
  Senokot senna
  Strepsils dichlorobenzyl alcohol & amylmetacresol
  Suboxone buprenorphine & naloxone
  Subutex buprenorphine
  Temgesic buprenorphine
  Unguentum M cetostearyl alcohol, glyceryl monostearate & paraffin
  V1003 buprenorphine
  V1004 buprenorphine
  V1005 buprenorphine

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.